Jose A. Fontenla

Dr. Jose A. Fontenla

Universidad de Santiago de Compostela, Santiago de Compostela, Spain
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in Carbohydrate Research
Verified
Journal Article
Closed access
CFCaridad Fernández
Caridad Fernández
ONOfelia Nieto
Ofelia Nieto
EREmilia Rivas
Emilia Rivas
GMGisela Montenegro
Gisela Montenegro
Jose A. FontenlaJose A. Fontenla
Jose A. Fontenla
AFAlfonso Fernández-Mayoralas
Alfonso Fernández-Mayoralas

1 May 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MMMaria Matos
Maria Matos
SVSantiago Vilar
Santiago Vilar
RGRosa Mª Gonzalez-Franco
Rosa Mª Gonzalez-Franco
EUEugenio Uriarte
Eugenio Uriarte
LSLourdes Santana
Lourdes Santana
Jose A. FontenlaJose A. Fontenla
Jose A. Fontenla

20 January 2003 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Jose Carlos Gonzalez-GomezJose Carlos Gonzalez-Gomez
Jose Carlos Gonzalez-Gomez
LSLourdes Santana
Lourdes Santana
EUEugenio Uriarte
Eugenio Uriarte
JBJose Brea
Jose Brea
MVM Villazón
M Villazón
Jose A. FontenlaJose A. Fontenla
Jose A. Fontenla

5 August 1994 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Jose A. FontenlaJose A. Fontenla
Jose A. Fontenla
JOJavier Osuna
Javier Osuna
ERElizabeth Rosa
Elizabeth Rosa
ECElena Castro
Elena Castro
TGTomas G-Ferreiro
Tomas G-Ferreiro
JRJesus Rodriguez
Jesus Rodriguez

17 March 2014 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
MMMaria Matos
Maria Matos
PJPatricia Janeiro
Patricia Janeiro
RFRosa María González Franco
Rosa María González Franco
SVSantiago Vilar
Santiago Vilar
NTNicholas P Tatonetti
Nicholas P Tatonetti
Dolores ViñaDolores Viña
Dolores Viña
Due to the complex etiology of neurodegenerative diseases, there is growing interest in multitarget drugs. In this study we synthesized and evaluated a new series of compounds, with benzo[f]coumarin structure, as potential inhibitors of MAO-A, MAO-B, AChE and BuChE. In vitro studies show that most of the studied compounds inhibited the activity of MAO-B in the nano- to micro-molar range. 3-(3´-methoxyphenyl)benzo[f]coumarin is the most active compound with an IC50 value against MAO-B of 2.44 nM. Most of the derivatives exhibited an important selectivity profile against the MAO-B isoform. Some of them also acted as in vitro inhibitors of BuChE, with 3-(2´-hydroxyphenyl)benzo[f]coumarin being the most active with an IC50 value of 1.13 µM. In addition, a theoretical study of the physicochemical properties of the new compounds, as well as a docking study in both MAO isoforms, were carried out. Important structure-activity relationships were obtained. Important preliminary structure-activity relationships were concluded from the experimental results. These results encourage us to further explore the potential of this chemical family as potential drug candidates for the treatment of Alzheimer's disease.

1 July 1999 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EREnrique Raviña
Enrique Raviña
JNJesús Negreira
Jesús Negreira
JCJosé Cid
José Cid
CMChristian F. Masaguer
Christian F. Masaguer
ERElizabeth Rosa
Elizabeth Rosa
Antonio CarrieriAntonio Carrieri
Antonio Carrieri